School of Medicine
Showing 1-10 of 18 Results
-
Michael S. Kapiloff, MD, PhD
Reinhard Family Professor, Professor (Research) of Ophthalmology and, by courtesy, of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.
URL to NCBI listing of all published works:
http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descending
For more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html -
James Regun Karmoker
Postdoctoral Scholar, Ophthalmology
BioDr. James Regun Karmoker started his career as a Lecturer at the University of Asia Pacific, Bangladesh, after completing his B. Pharm and MS Pharm Tech from the same university. He obtained a doctorate degree in Vision Science from the University of Oklahoma, USA, where he studied immune cell activation in the context of retinal pigment epithelium injury. Currently, he is a postdoctoral scholar in Prof. Mary Elizabeth Hartnett’s lab studying age-related macular degeneration.
-
Ryan Keenan, OD
Clinical Assistant Professor, Ophthalmology
BioDr. Keenan is a board-certified optometrist with the Stanford Health Care Byers Eye Institute and a clinical assistant professor in the Department of Ophthalmology.
Dr. Keenan diagnoses and treats a wide range of ocular and visual issues, such as vision problems related to stroke, intracranial lesions and tumors, and other neurological conditions. His clinical experience involves recognizing and caring for complex neuro-ophthalmic diseases. These include complications from diseases of the nervous system that adversely affect vision.
Dr. Keenan’s research interests include understanding genetic variations related to progressive weakness of the eye muscles. These conditions range from drooping eyelids to increasing limitations in eye movement.
Dr. Keenan has presented research and clinical findings to his peers at national and regional meetings, including the annual meetings of the American Academy of Optometry and the North American Neuro-Ophthalmology Society. -
Khizer Khaderi MD, MPH
Clinical Associate Professor, Ophthalmology
BioDr. Khizer Khaderi is a Clinical Associate Professor at the Byers Eye Institute at Stanford University. Khaderi is the Founding Director of the Stanford Human Perception Laboratory (HPL) and the Stanford Vision Performance Center (VPC). He also serves as faculty at the Stanford Institute for Human-Centered AI and the Wu Tsai Human Performance Alliance (HPA)
Khaderi is a renowned Neuro-Ophthalmic surgeon, technologist and futurist. Dr. Khaderi is pioneering the field of Symbiotics, defined as the convergence of human science + computer science. Khaderi developed the discipline of Symbiotics following initial interest from CS students interested in his research at the Stanford Human Perception Lab. Symbiotics involves a deep understanding in the principles of human systems and applying these principles computationally, to design and develop the next generation of human-centric technologies, where machines perceive, understand and respond to optimize the human experience. Dr. Khaderi envisions the application of Symbiotic principles as the key to unlocking ambient intelligence.
Khaderi has extensive domain expertise in artificial intelligence (AI), spatial computing (virtual reality (VR), augmented reality (AR), mixed reality (MxR)), wearables, gaming, IoT, Web3, applied neuroscience, human factors, and human-machine interfaces/interaction. His research interests include developing personalized human intelligent systems based on the human brain and sensory systems, developing technologies to optimize human performance, and combining biological and computational principles to expand our capabilities in research, clinical practice, and everyday life. Dr. Khaderi's approach to advance research interests and develop practical applications for everyday use is building technology, companies and collaborative partnerships across academia and industry.
Dr. Khaderi’s experience across industry sectors include consumer electronics, gaming, retail, life science, sports/Esports health care, Pharma, e-commerce, to name a few. He has developed novel technologies in these areas, and generated multiple invention patents. Selected as a “40 under 40”, he contributed to President Obama’s Council of Advisors on Science and Technology regarding vision technology and the aging population. He also advises multiple companies, venture firms and organizations including Apple, Google, Meta, Microsoft, Riot Games, Intel, Activision, Unity, Epic Games, NBA, Glaukos, the Global Esports Federation, the World Health Organization, the International Olympic Committee, the International Telecommunication Union, and the World Bank. -
Hyeonji Kim
Visiting Instructor/Lecturer, Ophthalmology
BioDr. Kim is a translational bioprinting researcher specializing in tissue engineering and ocular regenerative medicine. She holds a Ph.D. in Mechanical Engineering. Her research focuses on developing innovative therapeutic platforms for ocular diseases using 3D bioprinting, biomanufacturing, and regenerative medicine.
She has developed 3D-bioprinted corneal stromal constructs that replicate native collagen alignment and achieve transparency, successfully restoring visual function in preclinical beagle models and subsequent veterinary clinical applications. She also advanced a simplified in situ corneal therapy that has completed veterinary clinical trials and is now licensed for anticipated human trials. Currently, she is developing ocular therapeutic implants using advanced 3D printing approaches.
Dr. Kim has collaborated with regulatory authorities and preclinical evaluation agencies to define guidelines for 3D-printed combination medical devices and to conduct safety testing of bioprinted corneas. Her work has been internationally recognized, contributing to her university's ranking as 12th in Reuters’ 2019 “Top 100 Most Innovative Universities,” and spans drug delivery, diagnostic and therapeutic devices, personalized medicine, and translational ophthalmology. Her long-term vision is to engineer personalized therapeutic implants and biofabrication technologies that bridge fundamental science and clinical translation, initially focusing on restoring vision and ultimately expanding to regenerative therapies for multiple organ systems.
